Revolo Biotherapeutics to Present at May 2024 Medical Meetings
May 14, 2024 - Revolo Biotherapeutics, a pioneering company focused on developing therapies to reset the immune system for improved remission in autoimmune and allergic diseases, has announced its upcoming presentations at two significant medical conferences this May.
Revolo will be showcasing its research and developments at the American Thoracic Society (ATS) 2024 International Conference and the 6th Treg Directed Therapies Summit.
At the ATS 2024 International Conference, scheduled from May 17-22 in San Diego, Revolo will present a poster detailing their novel immunomodulatory peptide, IRL201104. The presentation is titled "IRL201104, A Novel Immunomodulatory Peptide, Shows Efficacy on Inflammatory Endpoints and Airway Hyperresponsiveness in a House Dust Mite Driven Model of Allergic Inflammation with or Without Poly I:C Exacerbation." The poster (number 804) will be discussed in Session D21, focusing on the control of airway inflammation and immune response in asthma, on May 22 from 8:15-10:15 a.m. PT in Room 31A-C at the San Diego Convention Center. Jorge De Alba, Vice President of Discovery and Translational Science at Revolo, will present the findings.
Meanwhile, at the 6th Treg Directed Therapies Summit in Boston from May 21-23, Revolo will deliver an oral presentation titled "‘1104, an immune-resetting peptide, for the treatment of allergic disease." This presentation, part of the Non-Cell Based Approaches track in the session "Utilizing Novel Platform Technology to Amplify Treg Induction In-Vivo," will take place on May 22 from 12:00-12:30 p.m. ET. Roly Foulkes, Chief Scientific Officer at Revolo, will lead the presentation.
Revolo Biotherapeutics is at the forefront of developing innovative therapies aimed at achieving remission in patients with autoimmune and allergic conditions by resetting the immune system. Their approach stands out by avoiding the immune suppression typically associated with current therapies. The company's two lead drug candidates, ‘1805 and ‘1104, function by shifting the immune system from an inflammatory state to a balanced, regulated state through the induction of T regulatory and B regulatory cells with just a single dose.
‘1104, a groundbreaking peptide, has successfully completed two Phase 2a trials involving patients with eosinophilic esophagitis (EoE) and those with allergen sensitivity. The drug is now progressing towards a Phase 2b trial in EoE and a Phase 2a trial in atopic dermatitis or asthma. Additionally, Revolo is investigating the potential of ‘1104 for treating other allergic diseases.
‘1805, a modified version of a crucial protein in immune function, is set to undergo a second Phase 2 clinical trial in patients with moderate-to-severe rheumatoid arthritis and a Phase 2a clinical trial for ulcerative colitis. The broad mechanism of action of Revolo's therapeutic candidates offers a promising platform for developing treatments across a range of autoimmune and allergic diseases.
Revolo Biotherapeutics continues to advance its mission of transforming the treatment landscape for autoimmune and allergic diseases through innovative therapies that reset the immune system and offer patients the possibility of sustained remission without the drawbacks of current treatment methods.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
